# Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan

> **NCT07704697** · PHASE3 · COMPLETED · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 346 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Experimental: Sacubitril/Allisartan and Amlodipine Group
- **DRUG:** Active Comparator: Sacubitril/Allisartan Group

## Key facts

- **NCT ID:** NCT07704697
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-23
- **Primary completion:** 2025-11-10
- **Final completion:** 2025-11-24
- **Target enrollment:** 346 (ACTUAL)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07704697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07704697, "Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07704697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*